News

Among second-line treatments for sarcoidosis, methotrexate is safer and associated with a lower risk of hospitalization, intensive care, the need for breathing support, and death compared to mycophenolate mofetil (MMF), according to a large real-world study. Methotrexate also showed a trend toward better efficacy and similar safety…

The Foundation for Sarcoidosis Research (FSR) brought together more than 40 leading clinicians and researchers from around the world for an in-person meeting of the FSR Global Sarcoidosis Clinic Alliance (FSR-GSCA) and the FSR Sarcoidosis Biomarker Summit. Together, these two gatherings marked a major step forward in international collaboration…

Researchers have identified 12 genes linked to chronic inflammation, immune dysregulation, and lung scarring that appear to be shared across both sarcoidosis and lung cancer. These genes were also tied to the Wnt signaling pathway, a system that helps regulate immune response and cell growth. Based on these findings,…

Only about one in four patients with unexplained, life-threatening arrhythmias are tested for cardiac sarcoidosis, even though medical guidelines call for it, according to a large worldwide study. As a result, cardiac sarcoidosis remains largely underdiagnosed, a problem that “carries significant risks, including delayed treatment and the potential for…

Combining angiotensin receptor blockers or ARBs — a type of medication used to lower blood pressure — with a class of diabetes medications called SGLT-2 inhibitors may help improve survival in adults with sarcoidosis, according to the findings of a new U.S. study. Data showed that the simultaneous use…

Only about 1 in 4 people with sarcoidosis were referred to a lung specialist within a year of diagnosis, according to data from a single center in Ohio. Because the lungs are the most commonly affected organ in sarcoidosis, seeing a pulmonologist is key for confirming lung involvement, monitoring…

Sarcoidosis appears to involve activation of several immune pathways, particularly those guiding responses against some common viruses. These are the findings of a study that looked for immune signatures of the disease by analyzing differences in gene activity between people with sarcoidosis and healthy controls. “These findings support the…

The Foundation for Sarcoidosis Research (FSR) marks 25 years of work to help people with sarcoidosis live better lives with an evening gala honoring leaders and partners driving research, care, and advocacy for the disease. Its 25th Anniversary Awards Gala — to be held Oct. 22 at…

Treatment with Atyr Pharma’s efzofitimod, known as EFZO-FIT for short, led to improvements in general health-related quality of life and reductions in fatigue for adults with pulmonary sarcoidosis taking part in a Phase 3 clinical trial, according to new data. Consistent with previously announced top-line results, these…

Treatment with rituximab can lead to meaningful improvements for some people with neurosarcoidosis affecting the brain and/or spinal cord — particularly those with hard-to-treat disease and involvement limited to some nerves. That’s according to a retrospective study of 19 people treated across four U.S. centers, which showed that…